BR112018067747A2 - proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne - Google Patents

proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne

Info

Publication number
BR112018067747A2
BR112018067747A2 BR112018067747A BR112018067747A BR112018067747A2 BR 112018067747 A2 BR112018067747 A2 BR 112018067747A2 BR 112018067747 A BR112018067747 A BR 112018067747A BR 112018067747 A BR112018067747 A BR 112018067747A BR 112018067747 A2 BR112018067747 A2 BR 112018067747A2
Authority
BR
Brazil
Prior art keywords
muscular dystrophy
folistatin
duchenne muscular
treatment
fusion proteins
Prior art date
Application number
BR112018067747A
Other languages
English (en)
Portuguese (pt)
Inventor
Iskenderian Andrea
W Norton Angela
Shen Chuan
Pan Clark
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of BR112018067747A2 publication Critical patent/BR112018067747A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
BR112018067747A 2016-03-04 2017-03-03 proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne BR112018067747A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303954P 2016-03-04 2016-03-04
PCT/US2017/020723 WO2017152090A2 (en) 2016-03-04 2017-03-03 Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
BR112018067747A2 true BR112018067747A2 (pt) 2019-01-08

Family

ID=58358939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067747A BR112018067747A2 (pt) 2016-03-04 2017-03-03 proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne

Country Status (14)

Country Link
US (1) US20200247856A1 (enExample)
EP (1) EP3423479A2 (enExample)
JP (1) JP2019509735A (enExample)
KR (1) KR20180137487A (enExample)
CN (1) CN109153708A (enExample)
AU (1) AU2017228475A1 (enExample)
BR (1) BR112018067747A2 (enExample)
CA (1) CA3016576A1 (enExample)
EA (1) EA201891990A1 (enExample)
IL (1) IL261397A (enExample)
MA (1) MA43588A (enExample)
MX (1) MX2018010470A (enExample)
SG (1) SG11201807400TA (enExample)
WO (1) WO2017152090A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180362604A1 (en) * 2017-05-12 2018-12-20 Shire Human Genetic Therapies, Inc. Recombinant Follistatin-FC Fusion Proteins and Use in Treating Duchenne Muscular Dystrophy
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
CN108303860B (zh) * 2018-03-26 2019-11-08 西安电子科技大学 一种用于无掩模光刻扫描的分布式曝光方法
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
WO2020160118A1 (en) 2019-01-29 2020-08-06 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
WO2023242251A1 (en) 2022-06-15 2023-12-21 UCB Biopharma SRL Follistatin-fc fusion proteins
IL317374A (en) 2022-06-15 2025-02-01 UCB Biopharma SRL Fusion protein for the prevention, treatment or alleviation of kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
AU2003217612A1 (en) * 2002-02-21 2003-09-09 Wyeth GASP1: a follistatin domain containing protein
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
HUE041335T2 (hu) * 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
TW201402611A (zh) * 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
PE20151612A1 (es) * 2012-12-18 2015-11-19 Novartis Ag Polipeptidos estabilizados del factor de crecimiento tipo insulina
MX362105B (es) * 2013-01-25 2019-01-04 Shire Human Genetic Therapies Folistatina en el tratamiento de distrofia muscular de duchenne.
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
CN106795224B (zh) * 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物

Also Published As

Publication number Publication date
CN109153708A (zh) 2019-01-04
US20200247856A1 (en) 2020-08-06
MX2018010470A (es) 2018-12-06
EP3423479A2 (en) 2019-01-09
WO2017152090A2 (en) 2017-09-08
KR20180137487A (ko) 2018-12-27
SG11201807400TA (en) 2018-09-27
WO2017152090A3 (en) 2017-10-19
EA201891990A1 (ru) 2019-04-30
CA3016576A1 (en) 2017-09-08
AU2017228475A1 (en) 2018-09-13
IL261397A (en) 2018-10-31
MA43588A (fr) 2021-06-02
JP2019509735A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
BR112018067747A2 (pt) proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne
BR112016030686A2 (pt) anticorpos anti tau humanizados
MX362105B (es) Folistatina en el tratamiento de distrofia muscular de duchenne.
BR112022007627A2 (pt) Compostos moduladores do glp-1r
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
MX2019013523A (es) Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.
AU2018338314A1 (en) Protein degraders and uses thereof
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112016012968A2 (pt) Métodos e composições para o tratamento de condições associadas com o envelhecimento
BR122020006914B8 (pt) Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018010160A8 (pt) inibidor da c1 esterase humana recombinante e usos do mesmo
BR112017008962A2 (pt) proteínas de fusão inibidoras de c1 esterase e usos das mesmas
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
MX2022001896A (es) Formulaciones anti-c5 de alta concentracion.
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112018069297A2 (pt) composição, e, métodos para induzir uma resposta imune e para tratar um indivíduo que foi diagnosticado com uma doença ou distúrbio
EP4234013A3 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
BR112018000771A2 (pt) anticorpos que se ligam à sortilina e inibem a ligação de progranulina, composições farmacêuticas, preparações dos mesmos, uso de anticorpos, kit e método de prevenção ou tratamento de uma doença associada a níveis diminuídos de pgrn
BR112014024751A2 (pt) antígenos de clostridium difficile
CL2020001798A1 (es) Dominio extracelular de una subunidad alfa del receptor fc para ige, composición farmacéutica que lo comprende y método para su producción.
CL2017002676A1 (es) Método de monomerizacion de moléculas recombinantes de anticuerpo
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
MX2017012828A (es) Anticuerpos anti-flt-1 para el tratamiento de distrofia muscular de duchenne.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]